search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Precision Medicine


References 1 Market Research Future. Precision Medicine Market Growth, Size and Share Expected to Expand with a 12.48% CAGR till the End-2022. Global Industry Trend Analysis 2019. [online] August 2019. Date accessed: 09/12/2019. (https://www.marketresearchfuture.com/reports /precision-medicine-market-925). 2 NICE. Pembrolizumab for untreated PD-L1- positive metastatic non-small-cell lung cancer. [online] 21/12/2018. Date accessed: 09/12/2019 (https://www.nice.org.uk/guidance/ta531/chapter /2-Information-about-pembrolizumab). 3 NICE. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. [online] 21/12/2018. Date accessed: 09/12/2019 (https://www.nice.org.uk/guidance/ta554/chapter /2-Information-about-tisagenlecleucel). 4 Kantarijan, H et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012. 119(9):1981-7. 5 Roy, L et al. Survival advantage from imatinib compared with the combination interferon- alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006. 108(5):1478-84. 6 Hochhaus, A et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Eng J Med. 2017. 376:917-27. 7 Perez, EA et al. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014. 32(33):3744-3752. 8 Haslam, A and Prasad, V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019. 2(5): e192535. 9West, HJ. No solid evidence, only hollow argument for universal tumor sequencing: show me the data. JAMA Oncol. 2016. 2:717-8. 10 Prasad, V. Perspective: the precision-oncology illusion. Nature 2016. 537:S63. 11 Aravanis, AM, Lee, M, Klausner, RD. Next- Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection. Cell. 2017. 168(4):571-574, 9. 12 Matthews, H, Hanison, J, Niramalan, N. “Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives. Proteomes. 2016. 4(3):28. 13 Quezada, H et al. Omics-based biomarkers: current status and potential use in the clinic. Bol Med Hosp Infant Mex. 2017. 74(3):219-226.


14 Foundation Medicine. FoundationOne CDx™: FoundationOne®CDx Technical Information. [online] July 2019. Date accessed: 09/12/2019. (https://assets.ctfassets.net/ vhribv12lmne/6Rt6csmCPuaguuqmgi2iY8/2fe839 f0e9075cf4a047bf241374e6af/F1CDx.Label.Tech nical_Info_Final_July_2019.pdf). 15 Ou, SI, Nagasaka, M, Zhu, VW. Liquid Biopsy to Identify Actionable Genomic Alterations. Am Soc Clin Oncol Educ Book. 2018. 38:978-997. 16 Hale, C. Grail’s third VC round brings funding total to $1.5B. Fierce Biotech. [online] 22/05/2018 Date accessed: 09/12/2019. (https://www.fiercebiotech.com/medtech/grail-s- third-vc-round-brings-funding-total-to-1-5- billion). 17 Novigenix. Colox. [online] Date accessed: 09/12/2019 (https://novigenix.com/colox/). 18 Ravazi, P et al. High-intensity sequencing reveals the sources of plasma circulating cell- free DNA variants. Nat med. 2019. 25:1928-37. 19 Smith, LM and Kelleher, NL. Proteoforms as the next proteomics currency. Science 2018. 359(6380):1106-7. 20 Martin, RM, Donovan, JL, Turner, EL. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality. The CAP Randomized Clinical Trial. JAMA. 2018;319(9):883-895. 21 Krishnamurti, U and Silverman, JF. HER2 in breast cancer: a review and update. Adv Anat Pathol. 2014. 21(2):100-7. 22 Udall, M et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Daign Pathol. 2018. 13:12. 23 Hudler, P, Kocevar, N, Komel, R. Proteomic Approaches in Biomarker Discovery: New Perspectives in Cancer Diagnostics. The Sci World J. 2014. Article ID 260348. 24 Glaser, V. Driving Mass Spec-Based Multiplexed Protein Biomarker Tests to the Clinic. GENENG NEWS. [online] 12/06/2014. Date accessed: 10/12/2019. (https://www.genengnews.com/insights/driving- mass-spec-based-multiplexed-protein- biomarker-tests-to-the-clinic/). 25 UROQUANT. [online] Date accessed: 10/12/2019. (https://www.uroquant.com/). 26 Miles, D and Papazisis, K. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Clin Breast Cancer. 2003. 3(Suppl. 4) S134-S138. 27 Miles, D et al. Phase III multicentre clinical trial of the sialyl-TN (sTn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011. 16:1092-1100. 28 Hsu, JM, Li, CW, Lai, YJ, Hung, MC. Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy. Cancer Res. 2018. 78(22):6349-6353. 29 Criexell, P and Linding, R. Cells, shared memory and breaking the PTM code. Mol Syst Biol. 2012. 8:598.


30 Benayoun, BA and Veitia, RA. A post- translational modification code for transcription factors: sorting through a sea of signals. Trends Cell Biol. 2009. 19(5):189-97. 31 Gu, B and Zhu, WG. Surf the Post- Translational Modification Network of p53 Regulation. Int J Biol Sci. 2012. 8(5): 672-684. 32 Hornbeck, PV et al. PhosphoSitePlus2014: mutations, PTMs and recalibrations. Nuc Acids Res. 2015. 43(Database issue); D512-520. 33 Methuselah Health. [online] Date accessed: 10/12/2019. (http://methuselah-health.com/ index.php#home). 34 Ntai, I et al. Integrated Bottom-Up and Top- Down Proteomics of Patient-Derived Breast Tumor Xenografts. Mol Cell Proteomics. 2016. 15(1): 45-56. 35 Mnatsakanyan, R et al. Detecting post- translational modification signatures as potential biomarkers in clinical mass spectrometry. Expert Rev Proteomics. 2018. 15(6):515-535. 36 Rodriguez, E, Schetters, STT, van Kooyk, Y. The Tumour Glyco-Code as a Novel Immune Checkpoint for Immunotherapy. Nat Rev Immunol. 18(3):204-211. 37 Smith, MP et al. A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom- up proteomic analyses. Proteomics. 2011. 11(11):2222-35. 38 Stephens, AN et al (2010). Post-translational modifications and protein-specific isoforms in endometriosis revealed by 2D DIGE. J Proteome Res. 2010. 9(5):2438-49. 39 Jackson, D et al. Considerations for powering a clinical proteomics study: Normal variability in the human plasma proteome. Proteomics Clin Appl. 2009. 3:394-407. 40 Jackson, D and Bramwell, D. Application of clinical assay quality control (QC) to multivariate proteomics data: a workflow exemplified by 2-DE QC. J Proteomics. 2013. 95:22-37. 41 Bramwell, D. An introduction to statistical process control in research proteomics. J Proteomics. 2013. 95:3-21. 42 Gibson, DS, Bramwell, D, Scaife, C. Difference In-Gel Electrophoresis: A High-Resolution Protein Biomarker Research Tool. In: Wang F. (eds) Biomarker Methods in Drug Discovery and Development. Methods in Pharmacology and Toxicology™. Humana Press. 2008. 43 Xiao, H, Woods, EC, Vukojicic, P, Bertozzi, CR. Precision Glycocalyx Editing as a Strategy for Cancer Immunotherapy. Proc Natl Acad Sci USA. 2016. 113(37):10304-9. 44 Bull, C et al. Targeting Aberrant Sialylation in Cancer Cells Using a Fluorinated Sialic Acid Analog Impairs Adhesion, Migration and in vivo Tumour Growth. Mol Cancer Ther. 2013. 12(10):1935-46.


Drug Discovery World Winter 2019/20


39


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68